COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
Ivermectin study #12 of 65
9/15 Early treatment study
Carvallo et al., medRxiv, doi:10.1101/2020.09.10.20191619 (Preprint)
Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19
Source   PDF   Share   Tweet
Prospective trial of ivermectin, dexamethasone, enoxaparin, and aspirin.
There was one death from 167 patients for 0.59% mortality, compared to an estimated overall mortality rate in Argentina of 2.1%.
For moderate to severe cases needing hospitalization, only 1 patient out of 32 died, authors compare to published rates of ~25%. There was 12 patients in the same hospital that were not treated with a 25% mortality rate.

Carvallo et al., 9/15/2020, prospective, Argentina, South America, preprint, mean age 55.7, 3 authors, dosage 36mg days 1, 8, dose varied depending on patient condition - mild 24mg, moderate 36mg, severe 48mg.
risk of death for hospitalized cases in study vs. cases in the same hospital not in the study, 87.9% lower, RR 0.12, p = 0.05, treatment 1 of 33 (3.0%), control 3 of 12 (25.0%), the only treatment death was a patient already in the ICU before treatment.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 65 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit